An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 46, 2015, Pages 14319-14324

  Ruseva, Marieta M ^a,c   Ramaglia, Valeria ^b   Morgan, B Paul ^a   Harris, Claire L ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CD59; Complement; CRIg; Therapy; Traumatic brain injury

Indexed keywords

CD59A ANTIGEN; COMPLEMENT COMPONENT C3B; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR; DIMER; IMMUNOGLOBULIN; INFLAMMASOME; INTERLEUKIN 1BETA; LYMPHOCYTE ANTIGEN; PLACEBO; UNCLASSIFIED DRUG; CD59 ANTIGEN; CD59A PROTEIN, MOUSE; CRIG PROTEIN, MOUSE; IL1B PROTEIN, MOUSE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL STRESS; COMPLEMENT DEPOSITION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; IN VITRO STUDY; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURFACE PROPERTY; TRAUMATIC BRAIN INJURY; ANIMAL; BRAIN INJURIES; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS, CD59; BRAIN INJURIES; COMPLEMENT C3B; COMPLEMENT MEMBRANE ATTACK COMPLEX; INFLAMMASOMES; INTERLEUKIN-1BETA; MICE; MICROGLIA; RECEPTORS, COMPLEMENT; RECOMBINANT PROTEINS;

EID: 84947461464     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1513698112     Document Type: Article

References (45)

1. Max JE, Robertson BA, Lansing AE (2001) The phenomenology of personality change due to traumatic brain injury in children and adolescents. J Neuropsychiatry Clin Neurosci 13(2):161-170.
2. Salmond CH, Sahakian BJ (2005) Cognitive outcome in traumatic brain injury survivors. Curr Opin Crit Care 11(2):111-116.
3. Bellander BM, Singhrao SK, Ohlsson M, Mattsson P, Svensson M (2001) Complement activation in the human brain after traumatic head injury. J Neurotrauma 18(12):1295-1311.
4. Burk AM, et al. (2012) Early complementopathy after multiple injuries in humans. Shock 37(4):348-354.
5. Stahel PF, et al. (2001) Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients with traumatic brain injury. J Neurotrauma 18(8):773-781.
6. Leinhase I, et al. (2006) Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. BMC Neurosci 7:55.
7. Stahel PF, et al. (2009) Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury inmice. J Neuroinflammation 6:2.
8. Kaczorowski SL, Schiding JK, Toth CA, Kochanek PM (1995) Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. J Cereb Blood Flow Metab 15(5):860-864.
9. Leinhase I, et al. (2006) Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp Neurol 199(2):454-464.
10. Sewell DL, et al. (2004) Complement C3 and C5 play critical roles in traumatic brain cryoinjury: Blocking effects on neutrophil extravasation by C5a receptor antagonist. J Neuroimmunol 155(1-2):55-63.
11. Leinhase I, et al. (2007) Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: A randomized placebo-controlled study in mice. J Neuroinflammation 4:13.
12. Holers VM (2008) The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 223:300-316.
13. Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: A key system for immune surveillance and homeostasis. Nat Immunol 11(9):785-797.
14. Fluiter K, Opperhuizen AL, Morgan BP, Baas F, Ramaglia V (2014) Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. J Immunol 192(5):2339-2348.
15. Ruseva MM, Morgan BP, Harris CL (2009) Targeting sites of complement activation by engineering selective drug delivery. Mol Immunology 46:2865.
16. Meri S, et al. (1990) Human protectin (CD59), an 18, 000-20, 000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71(1):1-9.
17. Qiao Q, et al. (2014) A novel CRIg-targeted complement inhibitor protects cells from complement damage. FASEB J 28(11):4986-4999.
18. Helmy KY, et al. (2006) CRIg: A macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124(5):915-927.
19. Pratt JR, Basheer SA, Sacks SH (2002) Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 8(6):582-587.
20. Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP (2002) The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 168(1):458-465.
21. Piddlesden SJ, et al. (1994) Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 152(11):5477-5484.
22. Ramaglia V, et al. (2007) The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J Neurosci 27(29):7663-7672.
23. Ma Y, et al. (2015) Protein kinase cα regulates the expression of complement receptor Ig in human monocyte-derived macrophages. J Immunol 194(6):2855-2861.
24. Laudisi F, et al. (2013) Cutting edge: The NLRP3 inflammasome links complementmediated inflammation and IL-1β release. J Immunol 191(3):1006-1010.
25. 2+ fluxes leading to NLRP3 inflammasome activation. J Cell Sci 126(Pt 13):2903-2913.
26. Rossi S, et al. (2014) Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. Mol Neurodegener 9:56.
27. Lai AY, Swayze RD, El-Husseini A, Song C (2006) Interleukin-1 beta modulates AMPA receptor expression and phosphorylation in hippocampal neurons. J Neuroimmunol 175(1-2):97-106.
28. Rostami E, et al. (2013) The terminal pathway of the complement system is activated in focal penetrating but not in mild diffuse traumatic brain injury. J Neurotrauma 30(23):1954-1965.
29. Zhang HF, Yu J, Bajwa E, Morrison SL, Tomlinson S (1999) Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest 103(1):55-61.
30. Mascia L, et al.; Sepsis Occurrence in Acutely Ill Patients (SOAP) Investigators (2008) Extracranial complications in patients with acute brain injury: A post-hoc analysis of the SOAP study. Intensive Care Med 34(4):720-727.
31. Plurad DS, et al. (2010) The association of race and survival from sepsis after injury. Am Surg 76(1):43-47.
32. Song H, et al. (2003) Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest 111(12):1875-1885.
33. Atkinson C, et al. (2005) Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 115(9):2444-2453.
34. Zhang R, Zheng ZY, Lin JS, Qu LJ, Zheng F (2012) The continual presence of C3d but not IgG glomerular capillary deposition in stage I idiopathic membranous nephropathy in patients receiving corticosteroid treatment. Diagn Pathol 7:109.
35. Dorado L, Millan M, Davalos A (2014) Reperfusion therapies for acute ischemic stroke: An update. Curr Cardiol Rev 10(4):327-335.
36. Longhi L, et al. (2009) C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice. Crit Care Med 37(2):659-665.
37. Baas F, Ramaglia V (2014) Uncovering the path to neurodegeneration from playingfield to battlefield. Traumatic Brain Injury, eds Sadaka F, Quinn T (Intech, Rijeka, Croatia), pp 79-106.
38. Reichert F, Rotshenker S (2003) Complement-receptor-3 and scavenger-receptor-AI/II mediatedmyelin phagocytosis inmicroglia and macrophages. Neurobiol Dis 12(1):65-72.
39. Rotshenker S (2003) Microglia and macrophage activation and the regulation of complement-receptor-3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and disease. J Mol Neurosci 21(1):65-72.
40. Rothwell NJ, Luheshi GN (2000) Interleukin 1 in the brain: Biology, pathology and therapeutic target. Trends Neurosci 23(12):618-625.
41. Charreau B, et al. (1994) Protection of rat endothelial cells from primate complementmediated lysis by expression of human CD59 and/or decay-accelerating factor. Transplantation 58(11):1222-1229.
42. Flierl MA, et al. (2009) Mouse closed head injury model induced by a weight-drop device. Nat Protoc 4(9):1328-1337.
43. Morgan BP (2000) Measurement of complement hemolytic activity, generation of complement-depleted sera, and production of hemolytic intermediates. Methods Mol Biol 150:61-71.
44. Harris CL, et al. (2003) Characterization of the mouse analogues of CD59 using novel monoclonal antibodies: Tissue distribution and functional comparison. Immunology 109(1):117-126.
45. Ruseva MM, Heurich M (2014) Purification and characterization of human and mouse complement C3. Methods Mol Biol 1100:75-91.